稳定期中段肾上腺髓质素原与慢阻肺严重急性加重相关
该研究汇总COMIC与PROMISE-COPD两个队列共1285例慢阻肺患者,比较稳定期血浆MR-proADM高(≥0.87 nmol/L)与低水平者的结局。高水平的患者发生需住院的严重AECOPD风险显著更高(校正HR 1.30,95%CI 1.01–1.68),但与社区获得性肺炎无关。
要点
- 稳定期MR-proADM≥0.87 nmol/L的慢阻肺患者严重急性加重风险更高。
- 严重AECOPD风险校正HR为1.30(95%CI 1.01–1.68)。
- MR-proADM与社区获得性肺炎的关联在校正后不显著。
核心结论
- 慢阻肺患者稳定期高水平的MR-proADM与严重AECOPD相关,但与CAP无关。
研究设计与样本
- 研究汇总COMIC与PROMISE-COPD两个队列共1285例慢阻肺患者的数据。
- 比较稳定期血浆MR-proADM高(≥0.87 nmol/L)与低(<0.87 nmol/L)水平患者的首次严重AECOPD时间。
- CAP分析仅使用COMIC数据(n=795)。
主要发现
- 高MR-proADM组发生严重AECOPD的风险显著高于低MR-proADM组,校正HR为1.30(95%CI 1.01–1.68)。
- 单因素分析中高MR-proADM与CAP风险升高相关(HR 1.93,95%CI 1.24–3.01)。
- 校正年龄、肺功能及既往AECOPD后,MR-proADM与CAP的关联不再显著(校正HR 1.10,95%CI 0.68–1.80)。
关键数值与推荐
- 稳定期血浆MR-proADM高水平定义为≥0.87 nmol/L,低水平定义为<0.87 nmol/L。
- 严重AECOPD的校正HR为1.30(95%CI 1.01–1.68)。
- CAP的单因素HR为1.93(95%CI 1.24–3.01),校正后HR为1.10(95%CI 0.68–1.80)。
临床怎么用
- 稳定期MR-proADM可作为慢阻肺患者严重急性加重风险的评估指标。
- MR-proADM升高不提示社区获得性肺炎风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated levels of midrange proadrenomedullin (MR-proADM) are associated with worse outcome in different diseases, including COPD. The association of stable-state MR-proADM with severe acute exacerbations of COPD (AECOPDs) requiring hospitalization, or with community-acquired pneumonia (CAP) in patients with COPD, has not been studied yet. The aim of this study was to evaluate the association of stable-state MR-proADM with severe AECOPD and CAP in patients with COPD. METHODS: This study pooled data of 1,285 patients from the Cohort of Mortality and Inflammation in COPD (COMIC) and PRedicting Outcome using systemic Markers In Severe Exacerbations of Chronic Obstructive Pulmonary Disease (PROMISE-COPD) cohort studies. Time until first severe AECOPD was compared between patients with high (≥ 0.87 nmol/L) or low (< 0.87 nmol/L) levels of plasma MR-proADM in stable state as previously defined. For time until first CAP, only COMIC data (n = 795) were available. RESULTS: Patients with COPD with high-level stable-state MR-proADM have a significantly higher risk for severe AECOPD compared with those with low-level MR-proADM with a corrected hazard ratio (HR) of 1.30 (95% CI, 1.01-1.68). Patients with high-level stable-state MR-proADM had a significantly higher risk for CAP compared with patients with COPD with low-level MR-proADM in univariate analysis (HR, 1.93; 95% CI, 1.24-3.01), but after correction for age, lung function, and previous AECOPD, the association was no longer significant (corrected HR, 1.10; 95% CI, 0.68-1.80). CONCLUSIONS: Stable-state high-level MR-proADM in patients with COPD is associated with severe AECOPD but not with CAP.
引用
- Citgez E, Zuur-Telgen M, van der Palen J, et al. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD. Chest. 2018. PMID: 29475034. doi:10.1016/j.chest.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。